v3.26.1
Revenue Recognition - Schedule of Revenue, Cost of Revenue, Gross Profit, Assets and Net Profit (Loss) (Details) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Schedule of Revenue, Cost of Revenue, Gross Profit, Assets and Net Profit (Loss) [Line Items]      
Revenue $ 2,639,353 $ 1,364,341  
Cost of revenue 872,862 420,447  
Gross profit $ 1,766,491    
Gross Profit % 66.93%    
Assets $ 5,009,582   $ 4,488,694
Net profit (loss) (876,274) $ (760,039)  
Global Stem Cells Group [Member]      
Schedule of Revenue, Cost of Revenue, Gross Profit, Assets and Net Profit (Loss) [Line Items]      
Revenue 2,639,353    
Cost of revenue 872,862    
Gross profit $ 1,766,491    
Gross Profit % 66.93%    
Assets $ 3,261,189    
Net profit (loss) 171,896    
Regenerative Medical Technology Group [Member]      
Schedule of Revenue, Cost of Revenue, Gross Profit, Assets and Net Profit (Loss) [Line Items]      
Revenue    
Cost of revenue    
Gross profit    
Gross Profit % 0.00%    
Assets $ 1,748,393    
Net profit (loss) $ (1,048,170)